7. (amended once) The antifibrillogenic agent of claim 1, wherein said peptide of Formula I is selected from the group consisting of:

Lys-Ile-Val-Phe-Phe-Ala	(SEQ ID NO:1);
Lys-Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:2);
Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:3);
Lys-Phe-Val-Phe-Phe-Ala	(SEQ ID NO:4);
Ala-Phe-Phe-Val-Leu-Lys	(SEQ ID NO:5);
Lys-Leu-Val-Phe	(SEQ ID NO:6);
Lys-Ala-Val-Phe-Phe-Ala	(SEQ ID NO:7);
Lys-Leu-Val-Phe-Phe	(SEQ ID NO:8);
Lys-Val-Val-Phe-Phe-Ala	(SEQ ID NO:9);
Lys-Ile-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:10);
Lys-Leu-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:11);
Lys-Phe-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:12);
Ala-Phe-Phe-Val-Leu-Lys-NH_2	(SEQ ID NO:13);
Lys-Leu-Val-Phe-NH_2	(SEQ ID NO:14);
Lys-Ala-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:15);
Lys-Leu-Val-Phe-Phe-NH_2	(SEQ ID NO:16);
Lys-Val-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:17);
Lys-Leu-Val-Phe-Phe-Ala-Gln	(SEQ ID NO:18);
Lys-Leu-Val-Phe-Phe-Ala-Gln-NH_2	(SEQ ID NO:19);
His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:20);
His-His-Gln-Lys	(SEQ ID NO:23); and
Gln-Lys-Leu-Val-Phe-Phe-NH_2	(SEQ ID NO:24).

A2

8. (amended once) The antifibrillogenic agent of claim 1, wherein the peptide of formula I is a peptide as set forth in SEQ ID NO:2.

15. (amended once) The labeled conjugate of claim 9, wherein said peptide of Formula I is selected from the group consisting of:

Lys-Ile-Val-Phe-Phe-Ala	(SEQ ID NO:1);
Lys-Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:2);
Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:3);
Lys-Phe-Val-Phe-Phe-Ala	(SEQ ID NO:4);
Ala-Phe-Phe-Val-Leu-Lys	(SEQ ID NO:5);
Lys-Leu-Val-Phe	(SEQ ID NO:6);
Lys-Ala-Val-Phe-Phe-Ala	(SEQ ID NO:7);
Lys-Leu-Val-Phe-Phe	(SEQ ID NO:8);
Lys-Val-Val-Phe-Phe-Ala	(SEQ ID NO:9);
Lys-Ile-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:10);
Lys-Leu-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:11);
Lys-Phe-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:12);
Ala-Phe-Phe-Val-Leu-Lys-NH_2	(SEQ ID NO:13);
Lys-Leu-Val-Phe-NH_2	(SEQ ID NO:14);
Lys-Ala-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:15);
Lys-Leu-Val-Phe-Phe-NH_2	(SEQ ID NO:16);
Lys-Val-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:17);
Lys-Leu-Val-Phe-Phe-Ala-Gln	(SEQ ID NO:18);
Lys-Leu-Val-Phe-Phe-Ala-Gln-NH_2	(SEQ ID NO:19);
His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:20);
His-His-Gln-Lys	(SEQ ID NO:23); and
Gln-Lys-Leu-Val-Phe-Phe-NH2	(SEQ ID NO:24).

A3

18. (amended once) A method for the treatment of amyloidosis disorders in a patient, which comprises administering to said patient a therapeutically effective amount of a peptide of Formula I as defined in claim 1.

A4

19. (amended once) A method for the treatment of amyloidosis disorders in a patient, which comprises administering to said patient a therapeutically effective amount of an antifibrillogenic agent as defined in claim 1.

A4

20. (amended once) A composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of a peptide of Formula I as defined in claim 1 in association with a pharmaceutically acceptable carrier.

21. (amended once) A composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of an antifibrillogenic agent as defined in claim 1 in association with a pharmaceutically acceptable carrier.

22. (amended once) A composition for *in vivo* imaging of amyloid deposits, which comprises a therapeutically effective amount of a labeled conjugate as defined in claim 9 in association with a pharmaceutically acceptable carrier.

A5

32. (amended once) A composition for inhibiting amyloidosis and/or for cytoprotection, which comprises a therapeutically effective amount of a peptide as defined in claim 31 in association with a pharmaceutically acceptable carrier.

34. (amended once) A process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming amyloid deposits, said process comprising contacting the cells *in vitro* with the peptide of Formula I as defined in claim 1.

A6

35. (amended once) The process of claim 34, wherein said peptide of Formula I or said antifibrillogenic compound causes breakdown of amyloid deposits, the deposits having been formed by said cells prior to said contact.

36. (amended once) The process of claim 34 , in which the cells

37. (new) The antifibrillogenic agent of claim 1, wherein the peptide of formula I is a peptide as set forth in SEQ ID NO:3.

A7

38. (new) A process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming amyloid deposits, said process comprising contacting the cells *in vitro* with the antifibrillogenic compound as defined in claim 1 for inhibiting amyloid deposit formation.

Pursuant to 37 CFR 1.121(c)(1)(ii), a marked up version of the claims showing the changes made appears as Appendix A of this Amendment.